A Global Perspective:
SWCRF’s scientific leaders share their expertise at an international symposium and convene with collaborators at the Shanghai Institute of Hematology
The fruits of the Samuel Waxman Cancer Research Foundation’s collaborative work with cancer researchers based at the Shanghai Institute of Hematology (SIH) were in the spotlight in November when SWCRF Chief Scientific Officer Jonathan Licht, M.D., and Co-Chair of the Scientific Advisory Board, Alan Rosmarin, M.D., traveled to Shanghai to attend the Chinese Society of Experimental Hematology meeting and Sino-U.S. Symposium on Medicine.
Dr. Licht delivered a talk titled Aberrant Histone Methylation in Multiple Myeloma at the Sino-U.S. Symposium, and both doctors were invited speakers at the Experimental Hematology Meeting, which focused on blood cell development, immunology, and malignant hematology, i.e. leukemias, lymphomas, and other blood disorders. In addition to Drs. Licht and Rosmarin, the slate of distinguished guests included Bruce Beutler, a recent Nobel laureate and leading expert in innate immunity, YW Kan, an international expert in red blood cell development, and Zhu Chen, the former Minister of Health in China and current honorary director of the SIH whose studies led to the contemporary treatment of a particular form of leukemia, known as acute promyelocytic leukemia.
After the symposium, Drs. Licht and Rosmarin visited sites of SWCRF-supported research at the Shanghai Institute of Hematology, a renowned research facility with which the SWCRF has partnered since 1982, and visited the Beijing Institute of Genomics.
“Dr. Waxman has long envisioned a Cancer Institute without Walls that brings together outstanding researchers from around the globe. During our visit to China, Dr. Licht and I reviewed results of the longstanding collaboration between Chinese and American scientists that has been promoted by the Sam Waxman Cancer Research Foundation,” said Dr. Rosmarin. “We saw the application of cutting-edge technology, including deep sequencing of the cancer genome, applied to leukemia and other blood cell disorders. These studies and related research will provide new opportunities for effective, targeted therapies of blood cancers.”
For more information about the Shanghai Institute of Hematology, visit http://www.sih.org.cn/html/home/